Company / Revenue
ENANTA PHARMACEUTICALS INC Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$79.2M
FY2025
5-year range
$79.2M / $205.2M
FY2021-FY2025
Trend
-8.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has declined for 5 consecutive years, from $207M in FY2020 to $79M in FY2025.
Based on SEC 10-K filings.
$79M in FY2025 with a 5-year CAGR of -17.5%.
Declined from $97M to $79M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -13.5%
- 5-Year CAGR
- -17.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's revenue has declined for 5 consecutive years.
- 5-year CAGR of -17.5%, indicating a declining trend.
- In FY2025, revenue decreased 8.1% year-over-year.
- Peak revenue was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $79.2M | -8.1% |
| FY2024 | $86.2M | -11.2% |
| FY2023 | $97.1M | -20.7% |
| FY2022 | $122.5M | -40.3% |
| FY2021 | $205.2M | -0.7% |
| FY2020 | $206.6M | +101.0% |
| FY2019 | $102.8M | +16.5% |
| FY2018 | $88.3M | -45.1% |
| FY2017 | $160.9M | +237.0% |
| FY2016 | $47.7M | +48.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026